News from omeros corporation

( Bloomberg:RTRKS,RICS:RTRKS)

Jun 02, 2014, 07:00 ET

Omeros Receives FDA Approval of Omidria™ for Use in Cataract and Other Intraocular Lens Replacement Procedures

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved Omidria™ (phenylephrine and...

May 12, 2014, 16:05 ET

Omeros Corporation Reports First Quarter 2014 Financial Results

Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing...

Apr 07, 2014, 07:00 ET

Omeros to Present at the 13th Annual Needham Healthcare Conference

 Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on...

Apr 03, 2014, 07:00 ET

Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies

 Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of...

Apr 01, 2014, 07:00 ET

Omeros Invited to Present on OMS824 Phase 2 Clinical Program at the Schizophrenia International Research Conference

 Omeros Corporation (NASDAQ: OMER) today announced that the company was invited by the organizers of the 2014 Biennial Conference of the...

Mar 21, 2014, 07:00 ET

Omeros to Present at BioCentury Future Leaders in the Biotech Industry Conference

 Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on...

Mar 19, 2014, 17:19 ET

Omeros Closes $40.25 Million Public Offering of Common Stock

 Omeros Corporation (NASDAQ: OMER) today announced that it has closed the underwritten public offering that was priced and allocated to...

Mar 14, 2014, 08:33 ET

Omeros Prices $35.0 Million Public Offering of Common Stock

 Omeros Corporation (NASDAQ: OMER) today announced that it has priced an underwritten public offering of 3,043,479 shares of its common...

Mar 13, 2014, 16:36 ET

Omeros Announces Proposed Public Offering of Common Stock

 Omeros Corporation (NASDAQ: OMER) today announced its intention to offer, subject to market and other conditions, shares of its common stock...

Mar 13, 2014, 16:16 ET

Omeros Corporation Reports Fourth Quarter and Year-End 2013 Financial Results

Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing...

Mar 10, 2014, 07:00 ET

Omeros Announces Positive OMS721 Data in Serum from Patients with aHUS

 Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding...

Mar 06, 2014, 07:00 ET

Omeros Reports Additional Positive Data from its OMS824 Phase 2a Schizophrenia Clinical Trial

Omeros Corporation (NASDAQ: OMER) today announced additional positive results from a Phase 2a clinical trial of OMS824, the company's...

Mar 05, 2014, 08:52 ET

Omeros Closes $32 Million Debt Financing, Receiving $12.6 Million in New Funds

 Omeros Corporation (NASDAQ: OMER) today announced that it has closed a senior credit facility with Oxford Finance and MidCap Financial, which...

Mar 04, 2014, 07:00 ET

Omeros Submits IND to Advance OMS721 Phase 2 Clinical Program

 Omeros Corporation (NASDAQ: OMER) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new...

Feb 26, 2014, 07:00 ET

Omeros to Present at Cowen and Company 34th Annual Health Care Conference

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on...

Feb 19, 2014, 07:00 ET

Omeros Announces Enrollment in Second Phase 2 Clinical Trial with OMS824

 Omeros Corporation (NASDAQ: OMER) today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's...

Feb 11, 2014, 07:00 ET

Omeros Reports Additional Positive Phase 1 Clinical Data for OMS824 for the Treatment of Cognitive Disorders

Omeros Corporation (NASDAQ: OMER) today announced additional positive data from its Phase 1 program for OMS824, the lead compound...

Feb 05, 2014, 07:00 ET

FDA Grants Fast Track Designation to Omeros' OMS824 Huntington's Disease Program

 Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to OMS824,...

Feb 03, 2014, 07:00 ET

Omeros Announces Positive Data after Completion of Dosing in Phase 1 Clinical Trial with OMS721

Omeros Corporation (NASDAQ: OMER) today announced positive data following completion of dosing in a Phase 1 clinical trial of OMS721, the company's...

Jan 29, 2014, 07:00 ET

Omeros Reports Positive Results from OMS824 Phase 2a Clinical Trial

Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge